POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride provides a source of potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse conduction, muscle contraction, and acid-base balance. Sodium chloride provides sodium and chloride ions, which are necessary for maintaining extracellular fluid volume and osmolality.
| Metabolism | Potassium and sodium are not metabolized; they are excreted primarily by the kidneys. Potassium is also excreted in feces and sweat. Sodium is mainly excreted in urine under the regulation of aldosterone and other hormones. |
| Excretion | Renal excretion of potassium is the primary route (approximately 90% of daily intake), with minimal fecal loss (about 10%). The sodium component is also predominantly renally excreted, with >99% of filtered sodium reabsorbed under normal conditions. |
| Half-life | Potassium: Not applicable as endogenous ion with tight homeostatic control; administered potassium distributes rapidly and is eliminated with a functional half-life of about 1-2 hours in the central compartment due to redistribution and renal excretion, but total body potassium turnover half-life is approximately 20-30 days. Sodium: Not applicable; administered sodium is rapidly equilibrated and renally regulated. |
| Protein binding | Potassium: Not significantly protein-bound (<1%). Sodium: Not significantly protein-bound (<1%). |
| Volume of Distribution | Potassium: Total body water (approximately 0.5 L/kg) with 98% intracellular; Vd for extracellular potassium is about 0.2 L/kg. Sodium: Primarily extracellular fluid, Vd approximately 0.2-0.3 L/kg. |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous infusion: Onset of effect on serum potassium and sodium concentrations is immediate (within minutes) as the solution is directly infused into the bloodstream. |
| Duration of Action | Intravenous infusion: Duration is dependent on infusion rate and ongoing losses; typically, effects on serum electrolytes last for as long as the infusion continues and for a short period after cessation (minutes to hours) until renal excretion and redistribution occur. |
| Molecular Weight | 74.55 |
Intravenous infusion: 0.037% potassium chloride in 0.9% sodium chloride solution; rate not to exceed 10 mEq/hour (or 10 mmol/hour) potassium; typical adult dose 20-40 mEq per day, adjusted based on serum potassium levels.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 20-50 mL/min: reduce maintenance dose by 25-50%; GFR <20 mL/min: avoid use or use with extreme caution, dose reduction of 50-75% and frequent monitoring of serum potassium. |
| Liver impairment | No specific dose adjustments for Child-Pugh class A, B, or C; however, monitor serum potassium closely due to potential metabolic disturbances. |
| Pediatric use | Intravenous infusion: 0.2-0.5 mEq/kg/hour (max 1 mEq/kg/day) for maintenance; for replacement, 0.3-1 mEq/kg/dose based on serum potassium deficit; rate not to exceed 0.5-1 mEq/kg/hour. |
| Geriatric use | Initiate at low end of adult dosing; monitor renal function and serum potassium more frequently due to age-related decline in renal function and increased risk of hyperkalemia. |
| 1st trimester | Potassium and sodium chloride are essential electrolytes; use is considered safe in recommended doses for correction of deficiencies. No known teratogenic risk. |
| 2nd trimester | Safe for maintenance or replacement therapy when clinically indicated. Monitor serum electrolytes to avoid hyperkalemia or hypernatremia. |
| 3rd trimester | Use with caution; excessive administration may cause maternal electrolyte disturbances affecting fetal homeostasis. Avoid in preeclampsia with hypervolemia. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium and sodium ions freely cross the placenta via active transport and diffusion, maintaining fetal-maternal electrolyte balance. No specific molecular weight data; ions have low molecular weight. |
| Breastfeeding | Potassium and sodium are normal constituents of breast milk. Administration of this solution does not pose a risk to the nursing infant when used at recommended doses. However, use the minimum effective dose and monitor maternal electrolyte levels. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER: Potassium chloride is a normal constituent of body fluids and is essential for cellular function. At physiological concentrations, no teratogenic effects are expected. However, hyperkalemia may occur with excessive administration, which can cause maternal cardiac arrhythmias and potentially fetal distress. No specific fetal malformations are associated with potassium chloride at replacement doses. First trimester: No known teratogenic risk with appropriate use. Second and third trimesters: Use cautiously to avoid hyperkalemia, which may affect fetal heart rate; monitor maternal serum potassium levels. |
| Fetal Monitoring | Monitor maternal serum potassium levels, renal function, and ECG for signs of hyperkalemia (e.g., peaked T waves, widened QRS). During labor and delivery, continuous fetal heart rate monitoring is recommended if maternal potassium levels are significantly altered or if large volumes are infused. Assess for signs of fluid overload if large volumes of 0.9% sodium chloride are administered. |
| Fertility Effects | No adverse effects on fertility have been reported with potassium chloride or 0.9% sodium chloride at therapeutic doses. Hyperkalemia or severe electrolyte imbalances could potentially disrupt reproductive function, but such effects are indirect and reversible upon correction of the underlying disturbance. |
■ FDA Black Box Warning
None
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaHypernatremiaSevere renal impairment with oliguria or anuriaAcute dehydrationConcomitant use of potassium-sparing diuretics (if potassium-containing)
| Precautions | Administration may cause hyperkalemia, especially in patients with renal impairment, or if given too rapidly. Hypernatremia may occur with excessive sodium administration. Use with caution in patients with heart failure, renal insufficiency, or conditions predisposing to fluid overload. Monitor serum electrolytes and fluid balance. Do not administer unless solution is clear and container is intact. |
| Food/Dietary | Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes, tomatoes) unless directed by your healthcare provider, as they may increase risk of hyperkalemia. Salt substitutes often contain potassium chloride and should be avoided. |
| Clinical Pearls | This solution is used for maintenance hydration and to correct or prevent hypokalemia. Monitor serum potassium levels and renal function. Do not administer undiluted; ensure compatibility with concurrent medications. Use with caution in patients with renal impairment, adrenal insufficiency, or digitalis toxicity. Rapid infusion may cause hyperkalemia and cardiac arrest. Maximum infusion rate: 10 mEq/h (0.037% KCl = 5 mEq/L). |
| Patient Advice | This medication is a potassium supplement given through your vein to maintain normal potassium levels. · Tell your healthcare provider if you have kidney problems, heart disease, or are taking any other medications. · You may feel warmth, tingling, or pain at the IV site; report any discomfort immediately. · Do not stop treatment abruptly without consulting your doctor. · Inform your provider if you develop muscle weakness, irregular heartbeat, or numbness. |
Loading safety data…